Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company specializing in targeted inflammatory and immunology therapies for dermatology, will participate in two upcoming healthcare conferences. CEO Brad Burnam is scheduled to present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (Virtual) on Wednesday, February 25, 2026, from 8:00 a.m. to 8:30 a.m. Eastern Time. He will also present at the 46th Annual TD Cowen Healthcare Conference at the Boston Marriott Copley Place on Monday, March 2, 2026, from 1:10 p.m. to 1:40 p.m. Eastern Time. The company will provide updates on its dermatology pipeline, including the ongoing Phase 2 clinical trial of GX-03 for moderate-to-severe atopic dermatitis, and will hold one-on-one meetings with institutional investors. Live webcasts of the presentations and replays (available for approximately 30 days) can be accessed in the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209275747) on February 09, 2026, and is solely responsible for the information contained therein.